Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA

Watchlist Manager
Sun Pharmaceutical Industries Ltd Logo
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Watchlist
Price: 1 795.3 INR 0.86% Market Closed
Market Cap: 4.3T INR
Have any thoughts about
Sun Pharmaceutical Industries Ltd?
Write Note

Sun Pharmaceutical Industries Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sun Pharmaceutical Industries Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Current Liabilities
â‚ą172.5B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
16%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Current Liabilities
â‚ą95.9B
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Current Liabilities
â‚ą54.5B
CAGR 3-Years
0%
CAGR 5-Years
5%
CAGR 10-Years
5%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Total Current Liabilities
â‚ą53.4B
CAGR 3-Years
-12%
CAGR 5-Years
-6%
CAGR 10-Years
7%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Current Liabilities
â‚ą48.5B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Current Liabilities
â‚ą21.2B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sun Pharmaceutical Industries Ltd
Glance View

Market Cap
4.3T INR
Industry
Pharmaceuticals

Sun Pharmaceutical Industries Ltd. is a leading global pharmaceutical company based in India, renowned for its commitment to producing high-quality generic and specialty medicines. Founded in 1983, Sun Pharma has evolved into one of the largest pharmaceutical companies in India and the fifth largest globally in the generic market. With a robust portfolio that encompasses various therapeutic areas, including cardiology, psychiatry, neurology, and oncology, the company has built a solid reputation for innovation and reliability. A strong emphasis on research and development drives Sun Pharma’s growth, helping it to continuously expand its product offerings and tap into new markets, as evidenced by its strategic acquisitions and partnerships over the years. For investors, Sun Pharmaceutical presents a compelling opportunity, underpinned by its solid financial performance and a forward-looking strategic vision. The company's extensive presence in over 150 countries combined with a diverse portfolio fuels its competitive edge in the global pharmaceutical landscape. With a solid track record of profitability and a commitment to enhancing shareholder value, Sun Pharma is well-positioned to capture growth in emerging markets and capitalize on advancements in biologics and complex generics. Moreover, the company’s focus on sustainability and ethical practices resonates in an increasingly socially conscious investment environment, making it an appealing prospect for investors looking to diversify their portfolios while supporting a responsible industry leader.

SUNPHARMA Intrinsic Value
1 046.73 INR
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Sun Pharmaceutical Industries Ltd's Total Current Liabilities?
Total Current Liabilities
172.5B INR

Based on the financial report for Sep 30, 2024, Sun Pharmaceutical Industries Ltd's Total Current Liabilities amounts to 172.5B INR.

What is Sun Pharmaceutical Industries Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
16%

Over the last year, the Total Current Liabilities growth was 15%. The average annual Total Current Liabilities growth rates for Sun Pharmaceutical Industries Ltd have been 5% over the past three years , 3% over the past five years , and 16% over the past ten years .

Back to Top